Published April 25, 2020
0 views Journal article Open Access Open Access

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.

Creators

  • 1. Sapienza University of Rome
  • 2. Marche Polytechnic University
  • 3. University of Padua
  • 4. University of Perugia
  • 5. University of Palermo
  • 6. University of Turin
  • 7. Cattedra Unesco "Educazione Alla Salute E Allo Sviluppo Sostenibile", Dipartimento Di Medicina Clinica E Chirurgia, Sezione Di Endocrinologia, Università Federico II Di Napoli, Naples, Italy

Description

Abbreviations SARS Severe acute respiratory syndrome GC Glucocorticoid CIRCI Critical illness relative corticosteroid insufficiency AI Adrenal insufficiency In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus statement on the tailoring of glucocorticoid replacement in adrenal insufficiency [1]. A few months later, a novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has been recognized as responsible for COVID-19. The outbreak has now reached pandemic level, with a high global mortality rate [2]. From February on, Italy has experienced an exponential rise in the infected which is estimated to reach 200,000 people, with an overall lethality of approximately 10% [3]. A recent Chinese series of nearly 50,000 patients with confirmed COVID-19 infection found that approximately one-out-of-five (19%) evolve towards severe (14%) or critical (5%) pneumonia [4]. Several clinical trials are now testing the therapeutic options to treat lung and extra-respiratory complications of SARS-CoV2 infection. While awaiting for a specific treatment strategy, the SIE task force met again to address the tailoring of corticosteroid replacement in adrenal insufficient patients coping with the stress related to COVID-19 infection.
Enabled by The Lens

Open Access

Licence Attribution (IMPLIED-OA)
Publisher Website Access full text